Table 2.

The ASCO RAS Mutational Testing of Colorectal Carcinoma Tissue (2015)

Genes to be testedRecommendation
KRAS RAS mutational testing of colorectal carcinoma tissue should be performed for all individuals who are being considered for anti-EGFR monoclonal antibody therapy (cetuximab and panitumumab).
Before treatment with anti-EGFR antibody therapy, individuals with mCRC should have their tumor tested for mutations in:
  • KRAS exons 2 (codons 12 and 13), 3 (codons 59 and 61) and 4 (codons 117 and 146)
  • NRAS exons 2 (codons 12 and 13), 3 (codons 59 and 61), and 4 (codons 117 and 146)
Anti-EGFR antibody therapy should only be considered for treatment of individuals with metastatic colorectal carcinoma who are identified as having tumors with no mutations detected after such extended RAS mutation analysis.
NRAS

This ASCO table is adapted from (2). EGFR, epidermal growth factor receptor; mCRC, metastatic colorectal cancer; ASCO, American Society of Clinical Oncology

From: Panitumumab Therapy and RAS and BRAF Genotype

Cover of Medical Genetics Summaries
Medical Genetics Summaries [Internet].
Pratt VM, Scott SA, Pirmohamed M, et al., editors.
Copyright Notice

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.